Illumina, Grail deal unlikely to get EU nod – Reuters
Georgejason/iStock Editorial via Getty Images


The shares of Illumina (NASDAQ:ILMN) fell in the morning hours Wednesday after Reuters reported that the EU antitrust regulators are likely to veto its acquisition of cancer test developer Grail.
Cloudy prospects for $8B cash-and-stock deal come amid uncertainty that the concessions Illumina (ILMN) offered last week to the European Commissions to address antitrust issues will be adequate to boost competition, according to people familiar with the matter.

As part of concessions, the life sciences company offered royalty-free global licenses for some of its patents and pledged a three-year patent agreement with Chinese rival BGI not to pursue any patent litigation in Europe.
Several days ago, the EU alleged that Illumina (ILMN) breached the blocâs merger rules with the early closure of the Grail acquisition in August.